Understanding Advanced Lipid Testing for Cardiovascular Risk Assessment

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. While traditional lipid panels measuring total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides provide valuable insights, they may not fully capture an individual’s cardiovascular risk. Advanced lipid testing goes beyond these basic metrics, offering a more detailed evaluation of lipoprotein particles and other markers linked to atherogenesis and cardiovascular events. Understanding these tests can guide clinicians in tailoring risk-reduction strategies for patients with complex lipid profiles or unexplained cardiovascular risk.

Key Components of Advanced Lipid Testing

1. Lipoprotein(a) [Lp(a)]:
   • Lp(a) is a genetically determined lipoprotein particle associated with an increased risk of atherosclerosis, coronary artery disease (CAD), and stroke. Unlike LDL, Lp(a) levels are not significantly affected by diet or lifestyle changes.
   • Healthy range: Below 30 mg/dL.¹
2. Apolipoprotein B (apoB):
   • ApoB is a structural protein found in atherogenic lipoproteins, including LDL, very low-density lipoprotein (VLDL), and Lp(a). Elevated apoB levels indicate a high number of atherogenic particles, which are directly linked to CVD risk.
   • Healthy range: Below 90 mg/dL for low-risk individuals and below 70 mg/dL for high-risk individuals.²
3. LDL Particle Number (LDL-P):
   • LDL-P measures the number of LDL particles rather than their cholesterol content. A high LDL-P indicates a greater number of small, dense LDL particles, which are more prone to oxidation and plaque formation.
   • Healthy range: Below 1,000 nmol/L.³
4. Small Dense LDL (sdLDL):
   • sdLDL particles are more atherogenic than larger, buoyant LDL particles due to their susceptibility to oxidation and prolonged circulation time.
   • Healthy range: Below 30 mg/dL.⁴
5. High-Sensitivity C-Reactive Protein (hs-CRP):
   • Although not a lipid marker, hs-CRP measures systemic inflammation and is an independent predictor of cardiovascular events. Combining hs-CRP with advanced lipid testing can provide a comprehensive risk assessment.
   • Healthy range: Below 1.0 mg/L (low risk), 1.0-3.0 mg/L (moderate risk), above 3.0 mg/L (high risk).⁵
6. Lipoprotein Subfraction Analysis:
   • This test divides lipoproteins into subcategories based on size and density, providing insights into the distribution of LDL, HDL, and VLDL particles. Patterns such as increased small LDL or reduced large HDL are associated with higher cardiovascular risk.
   • Healthy patterns: Higher levels of large HDL and lower levels of small dense LDL are preferable.⁶

RELATED:

Addressing Dyslipidemia Using Personalized Medicine with Mark Houston, MD

Additional Tests to Assess Cardiovascular Risk

1. Non-HDL Cholesterol:
   • Captures all atherogenic lipoproteins (LDL, VLDL, Lp(a)) and is a better predictor of CVD risk than LDL cholesterol alone.
   • Healthy range: Below 130 mg/dL for low-risk individuals and below 100 mg/dL for high-risk individuals.
2. Triglyceride-to-HDL Ratio:
   • A marker of insulin resistance and metabolic health. Elevated ratios are associated with increased CVD risk.
   • Healthy range: Below 2.0 in most individuals.
3. Remnant Cholesterol:
   • Measures cholesterol content in triglyceride-rich lipoproteins (VLDL and IDL). Elevated levels are independently associated with atherosclerosis.
   • Healthy range: Below 30 mg/dL.
4. Insulin Resistance and Glycemic Control:
   • Fasting Insulin and HOMA-IR: Markers of insulin resistance, a key driver of metabolic syndrome and CVD.
     • Healthy fasting insulin: Below 25 µU/mL.
     • Healthy HOMA-IR: Below 2.0.
   • Hemoglobin A1c (HbA1c): Reflects average blood glucose levels over the past 2-3 months. Useful for identifying diabetes or prediabetes.
     • Healthy range: Below 5.7% (normal), 5.7-6.4% (prediabetes), 6.5% and above (diabetes).
   • Oral Glucose Tolerance Test (OGTT): Detects impaired glucose tolerance and early diabetes.
     • Healthy fasting glucose: Below 100 mg/dL.
5. Thrombotic and Coagulation Markers:
   • Fibrinogen: Linked to clot formation and cardiovascular events.
     • Healthy range: 200-400 mg/dL.
   • D-Dimer: A marker of clot turnover. Persistent elevations may indicate increased risk of venous thromboembolism and CVD.
     • Healthy range: Below 0.5 mg/L.
   • Platelet Function Testing: Abnormal platelet activity is associated with increased thrombotic risk.
     • Normal platelet activity levels vary based on specific testing methods.
6. Vascular Health and Endothelial Function:
   • Carotid Intima-Media Thickness (CIMT): Assesses atherosclerosis and plaque burden in the carotid arteries.
     • Healthy range: CIMT below 0.8 mm is typically considered normal.
   • Coronary Artery Calcium (CAC) Score: Quantifies calcified plaque in coronary arteries. A strong predictor of future CVD events.
     • Healthy range: CAC score of 0 indicates no detectable plaque; scores above 100 signify increased risk.
   • Ankle-Brachial Index (ABI): Assesses peripheral arterial disease (PAD) and overall vascular health.
     • Healthy range: 1.0-1.4. Values below 0.9 suggest PAD.
7. Genetic and Novel Risk Markers:
   • Polygenic Risk Scores for CVD: Assesses genetic predisposition to coronary artery disease.
     • No established healthy range; results indicate relative genetic risk.
   • 9p21 Genetic Test: A specific genetic risk locus strongly associated with coronary artery disease.
     • Results indicate presence or absence of risk alleles.
   • Oxidized LDL: Measures oxidized forms of LDL, which play a critical role in atherosclerosis progression.
     • Healthy range: Below 60 U/L.
8. Advanced Biomarkers:
   • Myeloperoxidase (MPO): Reflects oxidative stress and inflammation within atherosclerotic plaques.
     • Healthy range: Below 500 pmol/L.
   • Homocysteine: Elevated levels are associated with endothelial dysfunction and thrombotic risk.
     • Healthy range: 5-15 µmol/L.
   • Galectin-3: A marker of fibrosis and inflammation linked to heart failure and adverse cardiovascular outcomes.
     • Healthy range: Below 18 ng/mL.
   • BNP or NT-proBNP: Biomarkers for cardiac strain. Elevated levels may indicate heart failure or subclinical cardiac dysfunction.
     • Healthy range: BNP below 100 pg/mL; NT-proBNP below 300 pg/mL.
9. Lifestyle and Behavioral Factors:
   • Sleep Study: Obstructive sleep apnea (OSA) is a significant risk factor for hypertension, atrial fibrillation, and CVD.
     • Healthy sleep studies indicate no apneic events.
   • Stress and Depression Assessment: Tools like the Perceived Stress Scale (PSS) or Patient Health Questionnaire (PHQ-9) can assess psychosocial contributors to CVD risk.
     • Healthy scores indicate low perceived stress or no clinical depression.

Clinical Applications of Advanced Lipid Testing

1. Risk Stratification:
   • Advanced lipid testing helps identify high-risk individuals who may not be flagged by traditional lipid panels. This is particularly valuable for patients with a history of premature CVD, metabolic syndrome, or diabetes.
2. Treatment Personalization:
   • These tests guide clinicians in selecting therapies beyond standard lipid-lowering medications. For example, elevated apoB may indicate the need for PCSK9 inhibitors, while high Lp(a) levels might prompt consideration of emerging therapies such as antisense oligonucleotides.
3. Monitoring Therapy Effectiveness:
   • Advanced lipid testing can assess the impact of interventions, such as statins, ezetimibe, or lifestyle changes, by evaluating improvements in lipoprotein particle numbers or subfractions.

Challenges and Considerations

While advanced lipid testing provides valuable insights, it is essential to consider the following:

• Cost and Accessibility: These tests are often more expensive and may not be covered by insurance, limiting their availability to some patients.
• Clinical Interpretation: Advanced lipid test results require careful interpretation within the context of the patient’s overall health and risk factors. Collaboration with lipid specialists may be beneficial in complex cases.

Integrating Advanced Lipid Testing into Practice

Advanced lipid testing should be considered for patients with:

• Unexplained cardiovascular events despite normal lipid panels.
• A strong family history of premature CVD.
• Elevated triglycerides, metabolic syndrome, or diabetes.
• Persistent cardiovascular risk factors despite optimal LDL cholesterol levels.

By incorporating these tests into clinical practice, healthcare providers can deliver more personalized and effective cardiovascular care. As research continues to evolve, advanced lipid testing will likely play an increasingly central role in identifying and managing cardiovascular risk.

¹ Kronenberg, F. (2016). Lipoprotein(a): Still an Enigma? Current Cardiology Reports, 18(12), 15.
² Sniderman, A.D., et al. (2019). ApoB in Risk Assessment and the Management of Lipids. European Heart Journal, 40(40), 3005-3013.
³ Cromwell, W.C., et al. (2007). LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study. Circulation, 116(13), 1906-1913.
⁴ Hoogeveen, R.C., et al. (2014). Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk: A Clearer Picture. Journal of the American College of Cardiology, 64(5), 485-497.
⁵ Ridker, P.M., et al. (2000). C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease. New England Journal of Medicine, 342(12), 836-843.
⁶ Rosenson, R.S., et al. (2011). Lipoprotein Subfractions and Cardiovascular Risk. Current Opinion in Lipidology, 22(5), 329-336.